We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
By Paul Vieira
OTTAWA--Canada said Friday it secured a deal with the Serum Institute of India to acquire two million doses of the organization's version of the Covid-19 vaccine produced by AstraZeneca PLC in partnership with Oxford University.
News of the deal emerged hours after Canada authorized use of AstraZeneca's Covid-19 vaccine, as well as the version produced by the Serum Institute, which is the world's largest maker of vaccines. Canada said on Feb. 12 it was in talks with the Serum Institute, which makes more than a billion doses a year for everything from polio to measles, mostly for export to emerging markets.
Canada said in a statement the first 500,000 doses from the Serum Institute will be delivered to Canada in the coming weeks for distribution to the provinces and territories, which are in charge of the inoculation process. The remaining 1.5 million doses will arrive by mid-May.
The Canadian government has agreed to purchase 20 million doses of the AstraZeneca-Oxford vaccine. AstraZeneca said in a statement it is working with Canadian officials to deliver doses as quickly as possible.
Write to Paul Vieira at paul.vieira@wsj.com
(END) Dow Jones Newswires
February 26, 2021 12:45 ET (17:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions